Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ...
Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...
Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 ...
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of ...
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 trial.
Adding nivolumab (Opdivo) to standard-of-care cisplatin radiotherapy (CRT) after surgery for locally advanced head and neck squamous cell carcinoma (HNSCC) in patients at a high risk for relapse ...
Two common immunotherapy drugs will now be subsidised for all advanced or metastatic cancers, providing a lifeline to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback